Disease · MONDO_0007254
breast cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. breast cancer. Diseases, record MONDO_0007254. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007254
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
BC, cancer of breast, malignant breast neoplasm, malignant breast tumor, malignant breast tumour, malignant neoplasm of breast, malignant neoplasm of the breast, malignant tumor of breast, malignant tumor of the breast, malignant tumour of breast, malignant tumour of the breast
- Open Targets
- Highest stage of its drugs
- Approval, for 82 of its 1,032 drugs, from ClinicalTrials.gov, DailyMed, FDA, PMDA and TTD
- Open Targets
Drugs1,032
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PACLITAXEL | CHEMBL428647 | Small molecule | Approval | DailyMed, PMDA and TTD | 758 | 751 | 705 | Drugs and targets |
| TRASTUZUMAB | CHEMBL1201585 | Antibody | Approval | ClinicalTrials.gov, DailyMed, PMDA and TTD | 745 | 728 | 725 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Approval | DailyMed | 486 | 484 | 476 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Approval | ClinicalTrials.gov and DailyMed | 406 | 404 | 404 | Drugs and targets |
| LETROZOLE | CHEMBL1444 | Small molecule | Approval | DailyMed | 396 | 394 | 388 | Drugs and targets |
| FULVESTRANT | CHEMBL1358 | Small molecule | Approval | DailyMed, PMDA and TTD | 392 | 388 | 383 | Drugs and targets |
| ANASTROZOLE | CHEMBL1399 | Small molecule | Approval | DailyMed and TTD | 242 | 240 | 230 | Drugs and targets |
| PERTUZUMAB | CHEMBL2007641 | Antibody | Approval | ClinicalTrials.gov, DailyMed, PMDA and TTD | 242 | 236 | 235 | Drugs and targets |
| EXEMESTANE | CHEMBL1200374 | Small molecule | Approval | DailyMed | 217 | 216 | 210 | Drugs and targets |
| PALBOCICLIB | CHEMBL189963 | Small molecule | Approval | DailyMed, PMDA and TTD | 216 | 213 | 213 | Drugs and targets |
1 to 10 of 1,032
See all 1,032 drugsTargets609
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ERBB2 | Epidermal growth factor receptor | 35 | Epidermal growth factor receptor inhibitor; ErbB-2/ErbB-3 heterodimer inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 cross-linking agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator; Receptor tyrosine-protein kinase erbB-2 binding agent | Approval | https://conductscience.org/library/genes/2064 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 32 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3791 | Drugs and targets |
| TUBB | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/203068 | Drugs and targets |
| TUBB1 | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/81027 | Drugs and targets |
| TUBB2A | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/7280 | Drugs and targets |
| TUBB2B | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/347733 | Drugs and targets |
| TUBB3 | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/10381 | Drugs and targets |
| TUBB4A | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/10382 | Drugs and targets |
| TUBB4B | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/10383 | Drugs and targets |
| TUBB6 | Tubulin | 31 | Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/84617 | Drugs and targets |
1 to 10 of 609
See all 609 targetsTrials4,781
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 76 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00310180 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Phase 3 | 10,273 | 2019-03-12 | Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7 | ANASTROZOLE, EXEMESTANE, LETROZOLE, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00036270 | Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane | Phase 3 | 9,779 | 2009-12-04 | Breast Neoplasms | EXEMESTANE, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | Phase 3 | 8,381 | 2014-08-18 | Neoplasms, Breast | LAPATINIB, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00127205 | S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. | Phase 3 | 6,097 | 2019-08-28 | Breast Cancer | CLODRONIC ACID, IBANDRONIC ACID, ZOLEDRONIC ACID ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study | Phase 3 | 5,796 | 2022-04-13 | Breast Cancer | PALBOCICLIB | Its record names the disease | ClinicalTrials.gov |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | Phase 3 | 5,637 | 2021-04-09 | Breast Cancer | ABEMACICLIB | Its record names the disease | ClinicalTrials.gov |
| NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | Phase 3 | 5,351 | 2012-10-31 | Breast Cancer | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00045032 | Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer | Phase 3 | 5,099 | 2017-04-27 | Breast Cancer | TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Phase 3 | 5,018 | 2023-06-27 | Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma | ANASTROZOLE, EXEMESTANE, LETROZOLE, TAMOXIFEN CITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | Phase 3 | 4,994 | 2019-09-04 | Breast Adenocarcinoma | BEVACIZUMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 4,781
See all 4,781 trialsComparisons in its trials1,000
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tamoxifen Followed by Exemestane vs Exemestane: serious adverse events | 784 of 4,814 | 831 of 4,852 | 9,666 | NCT00036270 | Trial comparisons |
| Palbociclib Plus Endocrine Therapy (Arm A) vs Endocrine Therapy Alone (Arm B): deaths from any cause | 99 of 2,841 | 76 of 2,902 | 5,743 | NCT02513394 | Trial comparisons |
| Palbociclib Plus Endocrine Therapy (Arm A) vs Endocrine Therapy Alone (Arm B): serious adverse events | 369 of 2,841 | 229 of 2,902 | 5,743 | NCT02513394 | Trial comparisons |
| 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: deaths from any cause | 38 of 2,791 | 36 of 2,800 | 5,591 | NCT03155997 | Trial comparisons |
| 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: serious adverse events | 344 of 2,791 | 202 of 2,800 | 5,591 | NCT03155997 | Trial comparisons |
| Chemo and Endocrine Therapy vs Endocrine Therapy Alone: deaths from any cause | 161 of 2,487 | 175 of 2,497 | 4,984 | NCT01272037 | Trial comparisons |
| Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: deaths from any cause | 170 of 2,426 | 146 of 2,425 | 4,851 | NCT00553410 | Trial comparisons |
| Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: serious adverse events | 1,004 of 2,411 | 1,052 of 2,417 | 4,828 | NCT00553410 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
1 to 10 of 1,000
See all 1,000 comparisons in its trialsPapers from its trials2,768
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007254
GET https://conductscience.org/api/diseases/v1/MONDO_0007254/drugs?page=2